Needham & Company Maintains a 'Hold' on King Pharmaceuticals (KG); Though Downside Risks Have Abated, Execution Reservations Will Keep Shares Grounded
Tweet Send to a Friend
Needham & Company maintains a 'Hold' on King Pharmaceuticals, Inc. (NYSE: KG).
KG’s 2Q10 financials were largely in-line as modest ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
KG’s 2Q10 financials were largely in-line as modest ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
